Pages that link to "Q41545522"
Jump to navigation
Jump to search
The following pages link to Jochen Utikal (Q41545522):
Displaying 50 items.
- Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway (Q24298961) (← links)
- The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression (Q28076760) (← links)
- Immortalization eliminates a roadblock during cellular reprogramming into iPS cells (Q28254388) (← links)
- Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases (Q28345662) (← links)
- Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma (Q28543960) (← links)
- Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (Q28553287) (← links)
- Induced pluripotent stem cells generated without viral integration (Q29614343) (← links)
- Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution (Q29616187) (← links)
- Improved survival with MEK inhibition in BRAF-mutated melanoma (Q29620663) (← links)
- Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up (Q30317552) (← links)
- Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. (Q31882118) (← links)
- Molecular genetics of Xeroderma pigmentosum variant. (Q33196452) (← links)
- Allergic contact dermatitis from colophony and turpentine in resins of untreated pine wood (Q34500313) (← links)
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma (Q34664981) (← links)
- Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells (Q35099880) (← links)
- Predominant telangiectatic erythema in linear atrophoderma of Moulin: novel variant or separate entity? (Q35565022) (← links)
- Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma (Q35611909) (← links)
- SOX5 is involved in balanced MITF regulation in human melanoma cells. (Q35939947) (← links)
- Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. (Q36153854) (← links)
- Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. (Q36256712) (← links)
- Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. (Q36397395) (← links)
- Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition (Q36413900) (← links)
- Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium (Q36444132) (← links)
- mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model (Q37079145) (← links)
- Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy. (Q37433032) (← links)
- From skin to the treatment of diseases--the possibilities of iPS cell research in dermatology. (Q37876469) (← links)
- Mediators of induced pluripotency and their role in cancer cells - current scientific knowledge and future perspectives. (Q38010413) (← links)
- Systemic therapy of non-resectable metastatic melanoma (Q38166572) (← links)
- De- and re-differentiation of the melanocytic lineage. (Q38173449) (← links)
- Extracellular adenosine metabolism in immune cells in melanoma (Q38206399) (← links)
- Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. (Q38207414) (← links)
- From skin to other cell types of the body. (Q38236462) (← links)
- Myeloid-derived suppressor cells in malignant melanoma. (Q38254999) (← links)
- New therapeutic options for advanced non-resectable malignant melanoma. (Q38321800) (← links)
- Function and significance of MicroRNAs in benign and malignant human stem cells (Q38550782) (← links)
- MicroRNAs as novel targets and tools in cancer therapy (Q38798381) (← links)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Q38802138) (← links)
- Multiple roles of NF1 in the melanocyte lineage (Q38828126) (← links)
- Impact of preconditioning with retinoic acid during early development on morphological and functional characteristics of human induced pluripotent stem cell-derived neurons (Q38871991) (← links)
- Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients (Q38944200) (← links)
- Myeloid-derived suppressor cells and tumor escape from immune surveillance. (Q38992562) (← links)
- A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. (Q39071313) (← links)
- The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas. (Q39108767) (← links)
- Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens. (Q39170177) (← links)
- CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma (Q39223523) (← links)
- Loss of tumorigenic potential upon transdifferentiation from keratinocytic into melanocytic lineage (Q39624380) (← links)
- Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression (Q39960081) (← links)
- Endothelial Notch1 Activity Facilitates Metastasis (Q40317866) (← links)
- D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. (Q40489634) (← links)
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (Q40875359) (← links)